11 completed, 4 recruiting, 2 withdrawn, 1 unknown. 6 Phase 2, 2 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Withdrawn 2 |
| Phase 1 | 2 | Withdrawn 2 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Agendia: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort Capecitabine, Endocrine-therapy, MammoPrint ® and BluePrint assays - Invasive Mammary Carcinoma, Metastatic Breast Cancer | Phase 2 | Recruiting | Sonya Reid | 64 | 2023-09-28 | 2026-01-20 |
| PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS Female Breast Cancer | Recruiting | Women's Cancer Study Group GmbH | 1470 | 2022-12-07 | 2026-08-05 | |
| Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk Anti-aromatase inhibitor - Breast Cancer | Phase 2 | Recruiting | UNICANCER | 696 | 2022-10-12 | 2026-07-21 |
| LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) LY3200882 - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Withdrawn | The Netherlands Cancer Institute | 2020-01-01 | 2025-09-05 | |
| The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer Tamoxifen Citrate, Letrozole, Exemestane - Breast Cancer | Phase 2 | Completed | Johns Hopkins University | 30 | 2019-02-20 | 2024-05-07 |
| Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer Galunisertib - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Withdrawn | The Netherlands Cancer Institute | 2018-08-24 | 2019-07-24 | |
| Vinorelbine in Advanced BRAF-like Colon Cancer Vinorelbine Tartrate - Colon Cancer | Phase 2 | Completed | The Netherlands Cancer Institute | 1 | 2018-03-01 | 2025-08-03 |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles MammaPrint, BluePrint, and Full-Genome Testing - Breast Cancer | Recruiting | Agendia | 30000 | 2017-04-28 | 2025-08-20 | |
| Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry Breast Cancer | Completed | Agendia | 481 | 2015-11-01 | 2018-06-27 | |
| PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe) MammaPrint, BluePrint, TargetPrint - Breast Cancer | Completed | Women's Cancer Study Group GmbH | 452 | 2015-04-01 | 2019-08-13 | |
| The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy Breastcancer, Invasive Breast Carcinoma by Gene Expression Profile | Completed | Diakonessenhuis, Utrecht | 660 | 2013-01-01 | 2017-02-15 | |
| PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score MammaPrint - Hormone Receptor Positive Malignant Neoplasm of Breast | Completed | Agendia | 820 | 2012-05-01 | 2016-01-29 | |
| The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients Chinese | Completed | Agendia | 64 | 2012-01-01 | 2019-07-02 | |
| MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy - Breast Cancer | Phase 4 | Completed | Agendia | 226 | 2011-10-01 | 2018-06-28 |
| NBRST: Prospective Neo-adjuvant REGISTRY Trial MammaPrint 70-gene expression profile, BluePrint 80 gene expression profile - Breast Cancer | Completed | Agendia | 1142 | 2011-07-01 | 2021-01-19 | |
| A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Colon Cancer | Unknown | Agendia | 1200 | 2008-09-01 | 2019-01-09 | |
| Validation of 70-gene MammaPrint Profile in Japanese Population Breast Cancer | Completed | Agendia | 102 | 2008-04-01 | 2015-06-23 | |
| Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes anthracycline-based, docetaxel and capecitabine, tamoxifen - Breast Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 6600 | 2007-02-01 | 2022-11-17 |
Breast Neoplasms (12) · Colonic Neoplasms (2) · Carcinoma, Ductal, Breast (1) · Carcinoma, Lobular (1)
Capecitabine (4) · Letrozole (2) · Tamoxifen (2) · Blueprint Asept (1) · Docetaxel (1) · LY-2157299 (1) · Trastuzumab (1) · Vinorelbine (1) · exemestane (1) · pertuzumab (1)
United States (9) · Netherlands (5) · Germany (3) · Austria (2) · France (2) · Japan (2) · Switzerland (2) · Canada (1) · China (1) · Denmark (1) · Greece (1) · Israel (1) · Spain (1) · Sweden (1) · United Kingdom (1)
A Bardelli, Prof (3) · A Cervantes, Prof (3) · J Tabernero, Prof (3) · R Bernards, Prof (3) · R Salazar, MD, PhD (3) · S Siena, Prof (3) · S Tejpar, Prof (3) · F Ciardiello, Prof (2) · Nadia Harbeck, Prof. Dr. (2) · Ulrike Nitz, Prof. Dr. (2) · Andreas Hartkopf, Prof. Dr. (1) · Charles E Cox, MD (1) · Emiel Rutgers, MD, PhD (1) · F Ciardello, Prof (1)
PMID 22051734, PMID 24667714, PMID 27557300, PMID 32005181, PMID 32083990, PMID 33721561, PMID 35476550, PMID 36108259, PMID 38241603, PMID 40796181, PMID 42341255
2005 (1), 2016 (1)